These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 9545119)
1. The blood glucose lowering effects of exercise and glibenclamide in patients with type 2 diabetes mellitus. Gudat U; Bungert S; Kemmer F; Heinemann L Diabet Med; 1998 Mar; 15(3):194-8. PubMed ID: 9545119 [TBL] [Abstract][Full Text] [Related]
2. The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide. Massi-Benedetti M; Herz M; Pfeiffer C Horm Metab Res; 1996 Sep; 28(9):451-5. PubMed ID: 8911982 [TBL] [Abstract][Full Text] [Related]
3. The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia. Rosak C; Haupt E; Walter T; Werner J Diabetes Nutr Metab; 2002 Jun; 15(3):143-51. PubMed ID: 12173728 [TBL] [Abstract][Full Text] [Related]
4. Daily blood glucose profiles of glibenclamide and gliclazide taken once or twice daily in elderly type 2 diabetic patients. Kigawa Y; Oba K; Futami-Suda S; Norose J; Yasuoka H; Suzuki K; Ouchi M; Watanabe K; Suzuki T; Nakano H Geriatr Gerontol Int; 2008 Sep; 8(3):160-5. PubMed ID: 18821999 [TBL] [Abstract][Full Text] [Related]
5. Combination of insulin and glibenclamide in the treatment of elderly non-insulin dependent (type 2) diabetic patients. Kyllästinen M; Groop L Ann Clin Res; 1985; 17(3):100-4. PubMed ID: 3931537 [TBL] [Abstract][Full Text] [Related]
6. The effects of metformin and glibenclamide on glucose metabolism, counter-regulatory hormones and cardiovascular responses in women with Type 2 diabetes during exercise of moderate intensity. Cunha MR; da Silva ME; Machado HA; Fukui RT; Correa MR; Santos RF; Wajchenberg BL; Rondon MU; Negrão CE; Ursich MJ Diabet Med; 2007 Jun; 24(6):592-9. PubMed ID: 17381497 [TBL] [Abstract][Full Text] [Related]
7. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes. Tan MH; Johns D; Strand J; Halse J; Madsbad S; Eriksson JW; Clausen J; Konkoy CS; Herz M; Diabet Med; 2004 Aug; 21(8):859-66. PubMed ID: 15270789 [TBL] [Abstract][Full Text] [Related]
8. [Long-term effect of combination glibenclamide-insulin treatment in the secondary failure of sulfonylurea therapy--results of a one-year double blind study]. Lundershausen R; Orban S; Pissarek D; Panzram G Wien Klin Wochenschr; 1987 Sep; 99(17):603-8. PubMed ID: 3118579 [TBL] [Abstract][Full Text] [Related]
9. The effect of octreotide on glucose and insulin levels in a patient with type 2 diabetes on glibenclamide. Lee PE; Meneilly GS Diabetes Metab; 1999 Sep; 25(4):347-9. PubMed ID: 10566126 [TBL] [Abstract][Full Text] [Related]
10. Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide. Yngen M; Ostenson CG; Hjemdahl P; Wallén NH Diabet Med; 2006 Feb; 23(2):134-40. PubMed ID: 16433710 [TBL] [Abstract][Full Text] [Related]
11. Effect of the oral hypoglycaemic sulphonylurea glibenclamide, a blocker of ATP-sensitive potassium channels, on walking distance in patients with intermittent claudication. Mortensen UM; Nielsen-Kudsk JE; Sondergaard HM; Jakobsen P; Jensen BS; Schmitz O; Nielsen TT Diabet Med; 2006 Mar; 23(3):327-30. PubMed ID: 16492219 [TBL] [Abstract][Full Text] [Related]
12. Serum C-peptide after 6 months on glibenclamide remains higher than during insulin treatment. Peacock I; Watts R; Selby C; Tattersall RB Diabetes Res; 1987 Oct; 6(2):57-9. PubMed ID: 3123115 [TBL] [Abstract][Full Text] [Related]
13. Cardiovascular, metabolic and hormonal responses to the progressive exercise performed to exhaustion in patients with type 2 diabetes treated with metformin or glyburide. Cunha MR; Silva ME; Machado HA; Fukui RT; Correia MR; Santos RF; Wajchenberg BL; Rocha DM; Rondon MU; Negrão CE; Ursich MJ Diabetes Obes Metab; 2008 Mar; 10(3):238-45. PubMed ID: 18269639 [TBL] [Abstract][Full Text] [Related]
14. Randomized study of glibenclamide versus traditional Chinese treatment in type 2 diabetic patients. Chinese-French Scientific Committee for the Study of Diabetes. Vray M; Attali JR Diabete Metab; 1995 Dec; 21(6):433-9. PubMed ID: 8593925 [TBL] [Abstract][Full Text] [Related]
15. Response of regimens of insulin therapy in type 2 diabetes mellitus subjects with secondary failure. Zargar AH; Masoodi SR; Laway BA; Wani AI; Bashir MI J Assoc Physicians India; 2002 May; 50(5):641-6. PubMed ID: 12186116 [TBL] [Abstract][Full Text] [Related]
16. Glucose disturbances and regulation with glibenclamide in thalassemia. Ladis V; Theodorides C; Palamidou F; Frissiras S; Berdousi H; Kattamis C J Pediatr Endocrinol Metab; 1998; 11 Suppl 3():871-8. PubMed ID: 10091160 [TBL] [Abstract][Full Text] [Related]
17. Intrapulmonary administration of natural honey solution, hyperosmolar dextrose or hypoosmolar distill water to normal individuals and to patients with type-2 diabetes mellitus or hypertension: their effects on blood glucose level, plasma insulin and C-peptide, blood pressure and peaked expiratory flow rate. Al-Waili N Eur J Med Res; 2003 Jul; 8(7):295-303. PubMed ID: 12911866 [TBL] [Abstract][Full Text] [Related]
18. The effect of multiple oral dosing of nimodipine on glibenclamide pharmacodynamics and pharmacokinetics in elderly patients with type-2 diabetes mellitus. Mück W; Heine PR; Breuel HP; Niklaus H; Horkulak J; Ahr G Int J Clin Pharmacol Ther; 1995 Feb; 33(2):89-94. PubMed ID: 7757317 [TBL] [Abstract][Full Text] [Related]
19. Enhancement of blood glucose lowering effect of a sulfonylurea when coadministered with an ACE inhibitor: results of a glucose-clamp study. Rave K; Flesch S; Kühn-Velten WN; Hompesch BC; Heinemann L; Heise T Diabetes Metab Res Rev; 2005; 21(5):459-64. PubMed ID: 15915547 [TBL] [Abstract][Full Text] [Related]
20. Glibenclamide improves postprandial hypertriglyceridaemia in type 2 diabetic patients by reducing chylomicrons but not the very low-density lipoprotein subfraction levels. Skrapari I; Perrea D; Ioannidis I; Karabina SA; Elisaf M; Tselepis AD; Karagiannacos P; Katsilambros N Diabet Med; 2001 Oct; 18(10):781-5. PubMed ID: 11678967 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]